Tumor profiling and the incidentalome: patient decisions and risks.

In recent years, the field of oncology has witnessed rapid advancements in genetic sequencing simultaneously with steeply declining costs of sequencing technology. As a result, genomics-driven cancer medicine and the use of tumor profiling are quickly becoming mainstays of cancer therapy. Oncology patients can benefit from tumor profiling by allowing the selection of targeted therapies tailored to their disease. However, it is increasingly recognized that the process of determining a tumor DNA sequence may lead to incidental discovery of underlying germline mutations which can impact other aspects of a patient's health, and that of their family. How to handle the 'incidentalome' has been the subject of recent public debate, yet patient education about the potential risks of tumor profiling remains sparse. Patient perspectives and clinical implications of the tumor incidentalome must be specifically addressed by the oncology community as tumor profiling expands to become a new standard of care.

[1]  J. Berg,et al.  A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing , 2015, Genetics in Medicine.

[2]  Bartha Maria Knoppers,et al.  Return of genetic testing results in the era of whole-genome sequencing , 2015, Nature Reviews Genetics.

[3]  Lacey Smith,et al.  Reporting Incidental Findings in Clinical Whole Exome Sequencing: Incorporation of the 2013 ACMG Recommendations into Current Practices of Genetic Counseling , 2015, Journal of Genetic Counseling.

[4]  G. Mills,et al.  Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. , 2015 .

[5]  Donavan T. Cheng,et al.  Tumor relevant germline findings in targeted tumor sequencing using matched normal DNA of 1,570 unselected cases. , 2015 .

[6]  Avni Santani,et al.  Actionable exomic incidental findings in 6503 participants: challenges of variant classification , 2015, Genome research.

[7]  Christine Weiner,et al.  Anticipate and communicate: Ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). , 2014, American journal of epidemiology.

[8]  Seema M Jamal,et al.  Attitudes of genetics professionals toward the return of incidental results from exome and whole-genome sequencing. , 2014, American journal of human genetics.

[9]  S. Hull,et al.  The unintended implications of blurring the line between research and clinical care in a genomic age. , 2014, Personalized medicine.

[10]  L. Garraway,et al.  Cancer patients' preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study. , 2014 .

[11]  A. McGuire,et al.  Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group , 2014, Genetics in Medicine.

[12]  N. Holtzman.  ACMG recommendations on incidental findings are flawed scientifically and ethically , 2013, Genetics in Medicine.

[13]  Y. Bombard,et al.  Revealing the incidentalome when targeting the tumor genome. , 2013, JAMA.

[14]  E. Hofstatter,et al.  The promise and pitfalls of genomics-driven cancer medicine. , 2013, The virtual mentor : VM.

[15]  Fiona A Miller,et al.  Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care , 2013, European Journal of Human Genetics.

[16]  M. Driessnack,et al.  ‘Information is information’: a public perspective on incidental findings in clinical and research genome‐based testing , 2013, Clinical genetics.

[17]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[18]  Robert C. Green,et al.  Ethics and Genomic Incidental Findings , 2013, Science.

[19]  Levi A Garraway,et al.  Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Hudis,et al.  ASCO's approach to a learning health care system in oncology. , 2013, Journal of oncology practice.

[21]  E. V. Van Allen,et al.  Clinical analysis and interpretation of cancer genome data. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Cuppen,et al.  Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Minden,et al.  Cancer patient perceptions on the ethical and legal issues related to biobanking , 2013, BMC Medical Genomics.

[24]  Ellen Wright Clayton,et al.  Managing incidental genomic findings: legal obligations of clinicians , 2013, Genetics in Medicine.

[25]  R. Weinshilboum,et al.  Incidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET) , 2013, Genome Medicine.

[26]  Tina Hambuch,et al.  Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. , 2012, The Journal of molecular diagnostics : JMD.

[27]  L. Garraway,et al.  Attitudes of patients with cancer about personalized medicine and somatic genetic testing. , 2012, Journal of oncology practice.

[28]  Kris Dierickx,et al.  To tell or not to tell? A systematic review of ethical reflections on incidental findings arising in genetics contexts , 2012, European Journal of Human Genetics.

[29]  Martha Driessnack,et al.  Researcher and institutional review board chair perspectives on incidental findings in genomic research. , 2012, Genetic testing and molecular biomarkers.

[30]  R. Steiner,et al.  “I'm fine; I'm just waiting for my disease” , 2011, Neurology.

[31]  Boris Pasche,et al.  Whole-genome sequencing: a step closer to personalized medicine. , 2011, JAMA.

[32]  Mildred K. Cho,et al.  Understanding Incidental Findings in the Context of Genetics and Genomics , 2008, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.

[33]  Harry Ostrer,et al.  Translating genomic research into clinical practice: promise and pitfalls. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.